Janet Pope Janetbirdope
7 years 4 months ago
You can taper prednisone for pts doing well on combination or monoRx with Tocilizumab in RA who achieved low disease activity or remission but with slightly more flares in RCT of steroid taper va not. Abstract OP0030 #EULAR2019 @RheumNow https://t.co/Mb1OVtnJ1R
Janet Pope Janetbirdope
7 years 4 months ago
EULAR Madrid is off to a great start. Madrid is not too hot compared to two years ago. Beautiful region to explore. Do you know where this castle from 12th c that inspired Disney castle is? @RheumNow #EULAR2019 https://t.co/N2znTe3EFW
Here are a few of the highlights from day 1 EULAR in Madrid.
At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.
EULAR | The European League Against Rheumatism eular_org
7 years 4 months ago
Reunite with old friends and extend your professional network at the #EULAR2019 Networking Platform in Hall 6. We hope you are enjoying your evening! https://t.co/zcqx9wHSmU
Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.Below is a collection of the industry press releases detailing the abstracts, authors and presentation times from EULAR 2019.
Dr. Dinesh Khanna sclerodermaUM
7 years 4 months ago
impact on mRSS in abatacept group whereas placebo did change (purple lines). Time for personalized medicine!! #EULAR2019 https://t.co/XmYLq8ddIp
Dr. Dinesh Khanna sclerodermaUM
7 years 4 months ago
Early SSC is very hetogeneous disease. Data from the ASSET trial @bmsnews @UMIntMed and Whitfield lab (funded by @NIAIDNews) shows 1. Skin gene expression can largely be divided into 3 large groups with 41% with Normal like expression!! 2. Patients RX with abatacept had striking
Loreto Carmona 🖖 carmona_loreto
7 years 4 months ago
We don’t take medications either because we can’t or because we don’t want to. Robert Horne on #adherence #EULAR2019 https://t.co/YUdLCfGErV
Dr. John Cush RheumNow
7 years 4 months ago
This was a great presentation - 36K ANA test, 7875 repeat ANAs (11% rheums 82% non-rheums) ~10% each went from Pos to Neg (or Neg to Pos) but only 5 new Rheumatic Dx made - incredibly low yield and low PPV https://t.co/Ng8Fg4k158
Dr. John Cush RheumNow
7 years 4 months ago
Tildrakizumab, an IL-12/p19 inhibitor, studied in 391 very active #PsA pts. Rx compared PBO vs 4 different doses and TIL showed superior ACR 20/50/70 responses (79.5%/52.6%/29.1% vs 24%PBO) and 80% PASI75 at wk24. #EULAR2019 LB0002 https://t.co/QKg0yDS28B
Leonard Calabrese LCalabreseDO
7 years 4 months ago
I am so sorry to be missing EULAR this yr but feeling better!!! Will be Skyping in to the satellite Friday discussing what really matters to patients!!! @CCalabreseDO @RheumNow #IL6 @arthdoc https://t.co/teXkmmeAuo
David Liew drdavidliew
7 years 4 months ago
Turned up to #EULAR2019 and immediately ran into three other Australians (separately). We’re all over this joint! @dr_rachelblack @tuna0sashimi 🇦🇺🇦🇺 @RheumNow https://t.co/kM7IHKQykf
Dr. John Cush RheumNow
7 years 4 months ago
Dr Jon Kay on “drift” of reference product. Lessons from Herceptin biosimilar development #eular2019 SP0014 https://t.co/uqWgYESe6N
